Análise da porcentagem da DNA ploidia e de células em fase S, determinada por citometria de fluxo e por outras variáveis prognosticas em carcinomas primários de mama
DOI:
https://doi.org/10.32635/2176-9745.RBC.1998v44n1.2797Palabras clave:
Câncer de Mama, Citometria de Fluxo, Proliferação Celular, Conteúdo de DNA, PrognósticoResumen
Analisaram-se a DNA ploidia e a porcentagem de células em fase S, determinadas por citometria de fluxo, em biópsias de 69 carcinomas mamários. Outras variáveis prognosticas foram estudadas: 1. clínicas (raça, idade, estado menstruai, estadiamento, tamanho do tumor e a avaliação dos linfonodos axilares); 2. histológicas (comprometimento metastático dos linfonodos axilares, embolização de células neoplásicas em vasos linfáticos e sanguíneos, grau de diferenciação histológica, número de mitoses e necrose tumoral); 3. Bioquímicas (receptores de estradiol e progesterona). Cotejaram-se estas variáveis com o estudo da DNA ploidia e porcentagem de fase S. Notou-se haver uma associação significativa entre a DNA diploidia em pacientes com idade acima de 50 anos, tumores de tamanho ou igual a 2,0 cm, receptores de estradiol e receptores de progesterona. Observou-se também uma associação significativa entre a porcentagem de fase S >7,15 e pacientes na pré-menopausa, receptores de estradiol negativo e comprometimento metastático linfonodal. Constatou-se que as pacientes com tumores classificados como DNA aneuplóides, com fase S maior que 7,15, apresentaram metástases mais freqüentes e sobrevida menor que aquelas com tumores DNA diplóides e fase S menor que 7,15. Sob o ponto de vista do prognóstico pode-se constatar a importância do estudo do DNA, particularmente para o grupo pNO. Verificou-se a viabilidade de esta técnica ser realizada em nossa rotina para o estudo prognóstico do câncer de mama.
Descargas
Citas
Ministério da Saúde. Rio de Janeiro 1991. Câncer no Brasil. Dados dos Registros de Base Populacional. Instituto Nacional de Câncer. Coordenação de Programas de Controle de Câncer, Rio de Janeiro, 1991.
Azevedo, G.; Mendonça, S. - Câncer no Brasil: um risco crescente. Rev Bras Cancerol, 38 (4): 167-76,1992.
Von Hansemann, D.P. - Studie überdie spezificitãt den altruismus und anaplasie der zellen. Berlin, Hirschwald,93-l 18,1983.
Greenough, R.B. -Varyingdegress of malignancy in cancer of the breast. J Câncer Res Clin Oncol, 9: 453-63,1925.
Dressler, L.; Clark, C.; Owens, M.; Pounds, G.; Oldaker, T.; McGuire, W. – DNA flow cytometry predicts for relapse in node negative breast cancer patients. In: Annual Meeting of American Society of Clinical Oncology, Proceedings,6:57,1987.
Koike, M.A.A.; Federico, M.H.H.; Roela, R.H.; Nogueira, C.R.; Barbosa, E.M. - Hormonal influences on kinetic properties of breast carcinoma cells and DNA analyses, Cytometry, 4(7): 85,1994.
Koike,M.A.A.; Roela, R.H.; Barbosa, E.M.; Federico, M.H.H. - Flow-cytometric DNA analyses and hormonal receptor status in breast cancer. Ciência e Cultura (Journal of the Brazilian Association for the Advancement of Science), 46 (1/2): 88-91, 1994.
McGuire, W.L.; Tandon,A.K.; Allaed, D.C.; Chamness, G.C.; Clark, G.M. - How to use prognostic factors in axillary node-negative breast cancer patients. J Nat Câncer Inst 82 (12): 1006-14, 1990. DOI: https://doi.org/10.1093/jnci/82.12.1006
Silvestrini, R.; Daidone, M.G.; DiFranzo, G. - Prognostic implication of labeling index versus estrogen receptors and tumor size in node negative breast cancer. Breast Cancer ResTreat, 7: 161-69, 1986. DOI: https://doi.org/10.1007/BF01806246
Hedley, D.W.; Clark, G.M.; Cornelisse, C.J.; Killander, D.; Kute, T.; Merkel, D. - Consensus review of the clinicai utility of DNA cytometry in carcinoma of the breast. Cytometry, 14:482-85,1993. DOI: https://doi.org/10.1002/cyto.990140505
Lei vonen, M.; Krogerus, L.; NordUng, S. – DNA analysis in advanced breast câncer patients. Cancer Det Prev, 18, 2: 87-96, 1994.
Batsaki, J.G.; Sneig, N.; El-Naggar, A.K. - Flow cytometry (DNA content and S phase fraction). Analysis of breast cancer. Cancer, 15(71):2151-53,1992(Supple-ment). DOI: https://doi.org/10.1002/1097-0142(19930315)71:6+<2151::AID-CNCR2820711604>3.0.CO;2-B
Robertson, J.F.R.; Fllis, I.O.; Pearson, D.; Flston, C.W.; Nicholson, R.L; Blamey, R.W. - Biological factors of prognostic significance in local advanced breast câncer. Breast Cancer Res Treat, 29: 259-64,1994. DOI: https://doi.org/10.1007/BF00666479
Raber, M.N.; Barlogie, B. - DNA flow cytometry of human solid tumors. Flow cytometry and sorting Wiley-Fisso. Inc. 2nd edition, 745-54,1990.
Kalra, R.; Camplejohn, R.S.; Horak, F.; Stuart, N.; Harris, A.F. - Grow factor receptor in human câncer and the relationship with cellular proliferation. Br J Cancer, 22,1993. Supplement XX.
Dinçol, D.; Timlick-Aller, C.; Küçük, Ô.; Gilman-Sachs, A.; Frekul, S.; Içli, F. – Tumor - cell heterogeneity of DNA ploidy in pre-menopausal node-positi ve breast câncer. J. FxpClin Câncer Res, 13 (3): 223-27, 1994.
Friedman,N.S.;Freedman,M.D.-Correlation of DNA cytometry and hormone receptors with axillary lymph node status in patients with carcinoma of the breast. Maryland MedJ, 4301): 963-65, 1995. 33
Taylor, I.W.;Musgrove, F. A.; Friedlander, M.F.; Foo, M. S.; Hedley, D.W. – Influence of age on the DNA ploidy leveis of breast tumors. Fur JCancerClin Oncol, 19: 623-28,1983. DOI: https://doi.org/10.1016/0277-5379(83)90178-5
Beerman,H.; Kelvin,P.M.; Hermans,J.; Van de Velde, C.J.H.; Cornelisse, C.J. -Prognostic significance of DNA ploidy in a series of 690 primary breast câncer patients. Int.J Câncer, 45: 34-9, 1990. DOI: https://doi.org/10.1002/ijc.2910450108
Fallenius, A.; Auer, G.U.;Carstensen, J.M. - Prognostic significance of DNA measurements in 409 consecutive breast câncer patients. Cancer,62:331-41, 1988. DOI: https://doi.org/10.1002/1097-0142(19880715)62:2<331::AID-CNCR2820620218>3.0.CO;2-8
Mink,D.; Von-Tongelen,B.; Villena,H.C.; Heiss, C.; Schimidt, W. - Breast cancer and prognostic factors : tumor size, degree of differenciation, proliferation kinetics and expression hormone receptors. Fur J GynaecolOncol, 15(6): 424-36, 1994.
Merkel,D£.;McGuire,W.L.-Ploidy,proliferative activity and prognosis DNA flow cytometry of solid tumors. Cancer,65; 1194-205, 1990 DOI: https://doi.org/10.1002/1097-0142(19900301)65:5<1194::AID-CNCR2820650528>3.0.CO;2-M
Erhardt, K.; Auer,G.;Folin, A.;Silfversward, C.; Kool, L. - Comparison between histologic type, estrogen receptor and nuclear DNA content in mammary carcinoma. Am J Clin Oncol, 9 (1): 83-9, 1986. DOI: https://doi.org/10.1097/00000421-198602000-00019
Hedley, D.W.; Rugg, C.A.; Ng, A.B.P.; Taylor, LW. - Influence of celular DNA content and disease-free survival of stage II breast câncer patients. Câncer Res, 44:5395-98,1984.
Baildam, A.D.; Zaloudik, J.; Howell, A.; Bames, D.M.; Tumbull, F.; Swindell, R- DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. Br J Cancer, 55:553-9,1986. DOI: https://doi.org/10.1038/bjc.1987.113
Stal, O.; Carstensen, J.M.; Wingren, S.; Rutqvist, F.F.; Skoog, F. - S-phase fraction to survival after recurrence of breast cancer. ActaOncol, 33(4): 423-29,1994. DOI: https://doi.org/10.3109/02841869409098439
Stal, O.; Wingren, S.; Carstensen, J. – Prognostic value of DNA ploidy ans S-phase fraction in relation to estrogen receptor contente and clinicopathological variables in primary breast câncer. Fur J Câncer Clin Oncol, 25: 3019,1989. DOI: https://doi.org/10.1016/0277-5379(89)90023-0
Witzig, T.F.; Ingle, J.N.; Cha, S.S.; Shaid, D.J.; Tabery, R.L.; Wold, L.F.; Grant, C.; Gonchoroffn, J.; Katzmann, J. A. - DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer, 74(6): 1752-61,1994. DOI: https://doi.org/10.1002/1097-0142(19940915)74:6<1752::AID-CNCR2820740618>3.0.CO;2-5
Shankey, T.V.; Rabinovitch, P.C.; Bagwell, B.; Bayer, K.D.; Duque, R.F.; Hedley, D. W.; Mayall, B.H.; Wheeless, F. - Guidelines for implementation of clinicai DNA cytometry. Cytometry, 14: 427-77, 1993. DOI: https://doi.org/10.1002/cyto.990140503
Baldetrop, B.; Bendahl, P.O.; Femo,M.; Alanen, K.; DeUe, U.; Falkmer, U.; Hansson-Aggesjo, B.; Hockenstrom, T.; Lindgren, A.; Mossberg, F.; Nordling, S.; Sigurdsson, H.; Stal, O.; Visakorpi, T. - Reproducibility in DNAflow cytometric analysis of breast cancer. Commun. CUnCy-tometry, 22(2): 115-27,1995. DOI: https://doi.org/10.1002/cyto.990220207
Tubiana, M.; Koscielny, S. - Cell kinetics, grow rate and the natural history of breast cancer. The HeusonMemorial Lecture. Fur JCancerClin Oncol,24(l):9-14,1988. DOI: https://doi.org/10.1016/0277-5379(88)90170-8
Koester, S.K.; Maenpaa, J.U.; Wiebe, V.J.; B aker, W. J.; Wurz, G.T.; Seymour, R.C.; Koehler, R.E.; De Gregorio,M.W. -Flowcytometry: potetial utility in monitoring drug effects in breast câncer. Breast Cancer Res Treat, 32:57-65,1994. DOI: https://doi.org/10.1007/BF00666206
Daidone, M.G.; Silvestrini,R.; Luisi, A.; Mastore, M.; Benini, E.; Veneroni, S.; Brambilla, C.; Ferrari, L.; Grecco, M.; Andreola, S.; Veronesi, U. - Changes in biological markers after primary chemotherapy for breast cancers. Int J Câncer,61:301-05,1995. DOI: https://doi.org/10.1002/ijc.2910610304
Hietanen, P.; Blomqvist, C.; Wasenius, V.M.; Niskanen, E.; Franssila, K.; Nordling, S. – Do DNA ploidy and S-phase frac-tion in primary tumor predict the response to chemotherapy in metastatic breast cancer? Br J Câncer, 71: 1029-32,1995. DOI: https://doi.org/10.1038/bjc.1995.198
